"
Team:Cornell/Business
From 2011.igem.org
Project Description |
Future Directions |
Business Development |
Outreach/HP |
Safety
Business Cost Analysis
We have created a system in which products can be created continuously instead of in large batches. The following is an analysis of how our system matches up with current industrial standards.
Capital Expenditure
The batch production process has an advantage over our system in that it requires less capital and has a better economy of scale. Our system presents a linear economy of scale because we need to run chips in parallel to create more product. Batch production has a near-logarithmic economy of scale, since scaling up production (by increasing the size of the batch and overall machine) costs less up to a reasonable level.
Operating Expenditure
Batch production has a lower cost of operation for relatively cheap bio-pharmaceuticals. However, operating cost can climb steeply if the yield is low or quality is important. For most expensive pharmaceuticals, some or all of the following factors have the potential to raise costs:
- Presence of side reactions, where resources are used to produce unwanted byproducts instead of the target product.
- Toxic intermediates, which can often kill the host cell before large yields of the target product can be reached.
- Pharmaceuticals are created intracellularly. In order to extract the products, companies must lyse cells and purify the products. About 50% of the cost of creating intracellular pharmaceuticals is in the cost of purification. There are often 5-7 steps required in purification to remove all cell lysate, including organelles, unwanted proteins, DNA, etc.
- Quality factors, such as pH, temperature, concentration, etc., must be highly regulated.
- Different temperature, pH, etc. may be needed for different steps in the overall reaction. For example, even if it is known that a pH of 5 optimizes the efficiency of the first step in a reaction, the optimal pH of the second step may not be the same. It is difficult to modulate the conditions within cells effectively, so optimal reaction conditions may not be achievable for every step in production.
- Quality factors must be at a very specific value. Since mixing in a batch-processing does not perfectly homogenize the solution, there may be local variation in reaction conditions.
How our system addresses the challenges in batch processing:
- In the cell, the formation of byproducts would reduce the yield of the target pharmaceutical. BioFactory limits side reactions by organizing enzymes linearly in the order required by the desired biochemical pathway. Thus, intermediates immediately encounter the correct enzyme, driving them towards the target product in isolation from cellular enzymes or molecules which could participate in side reactions.
- BioFactory is a cell-free system. Therefore, toxic intermediates in the biochemical pathway are no longer an inhibition to production.
- Purification steps in BioFactory would be significantly cheaper than those currently required by industry methods. While some purification steps may still be needed, as perfect, 100%, yield is impossible, the cell-free method eliminates many steps in the purification process. The key potential for eliminating purification steps lies in the cell-free aspect of BioFactory: as the pathway's enzymes are extracted from the cell lysate via the streptavidin-biotin interaction, output from BioFactory would be free of cell components such as DNA or cell debris.
- A modular system allows for optimal reaction conditions at each step, because each step occurs in a different section of the system. In our system, each step would occur in a different microfluidic chip. This feature may enable our process to significantly increase yield as compared to the batch process system. Furthermore, our reaction mixture will be homogenous due to smaller volumes of reaction.
